Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSK | P41240 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FAP | Q12884 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4930706 | 1.00 | CSK (0.59) | CSKMMP2LMNADPP4DPP7 | |
| SCHEMBL4926634 | 0.88 | MAOB (0.60) | CSKMMP2MEN1KMT2A | |
| SCHEMBL4926623 | 0.88 | MAOB (0.60) | CSKMMP2MEN1KMT2A | |
| SCHEMBL6798022 | 0.86 | MMP2 (0.56) | MMP2LMNADPP4DPP7LOXL2 | |
| SCHEMBL7065251 | 0.86 | MMP2 (0.56) | MMP2LMNADPP4DPP7LOXL2 | |
| SCHEMBL7065249 | 0.86 | MMP2 (0.56) | MMP2LMNADPP4DPP7LOXL2 | |
| SCHEMBL6522414 | 0.85 | MMP2 (0.61) | MMP2LMNADPP4DPP7LOXL2 | |
| Hydrochloric Acid SCHEMBL6803379 | 0.85 | MMP2 (0.55) | MMP2LMNADPP4DPP7LOXL2 | |
| Hydrochloric Acid SCHEMBL6803383 | 0.85 | MMP2 (0.55) | MMP2LMNADPP4DPP7LOXL2 | |
| SCHEMBL6100385 | 0.82 | MMP2 (0.59) | MMP2LMNADPP4DPP7LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | KUREHA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1707560-A1 | HYDROXAMIC ACID DERIVATIVE AND AGE GENERATION INHIBITOR CONTAINING THE DERIVATIVE | Kureha Corporation (JP) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132539-A1 | Hydroxamic Acid Derivative And Age Generation Inhibitor Containing The Derivative | HDAC5, HDAC1, HDAC9 | CSK 2328/4885MMP2 97/4885LMNA 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.